386 related articles for article (PubMed ID: 18201278)
1. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.
Ozaki K; Kishikawa F; Tanaka M; Sakamoto T; Tanimura S; Kohno M
Cancer Sci; 2008 Feb; 99(2):376-84. PubMed ID: 18201278
[TBL] [Abstract][Full Text] [Related]
2. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
Kim MS; Blake M; Baek JH; Kohlhagen G; Pommier Y; Carrier F
Cancer Res; 2003 Nov; 63(21):7291-300. PubMed ID: 14612526
[TBL] [Abstract][Full Text] [Related]
4. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
7. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells.
Sato T; Suzuki M; Sato Y; Echigo S; Rikiishi H
Int J Oncol; 2006 May; 28(5):1233-41. PubMed ID: 16596240
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Frønsdal K; Saatcioglu F
Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
[TBL] [Abstract][Full Text] [Related]
9. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Adachi M; Zhang Y; Zhao X; Minami T; Kawamura R; Hinoda Y; Imai K
Clin Cancer Res; 2004 Jun; 10(11):3853-62. PubMed ID: 15173094
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death.
Ozaki K; Minoda A; Kishikawa F; Kohno M
Biochem Biophys Res Commun; 2006 Jan; 339(4):1171-7. PubMed ID: 16338224
[TBL] [Abstract][Full Text] [Related]
12. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
13. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species.
Kang J; Chen J; Shi Y; Jia J; Zhang Y
Biochem Pharmacol; 2005 Apr; 69(8):1205-13. PubMed ID: 15794941
[TBL] [Abstract][Full Text] [Related]
14. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin induces apoptosis with profile of large-scale DNA fragmentation and without DNA ladder in anaplastic thyroid carcinoma cells via histone hyperacetylation.
Rho JH; Kang DY; Park KJ; Choi HJ; Lee HS; Yee SB; Yoo YH
Int J Oncol; 2005 Aug; 27(2):465-71. PubMed ID: 16010429
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylation as a target for radiosensitization.
Cerna D; Camphausen K; Tofilon PJ
Curr Top Dev Biol; 2006; 73():173-204. PubMed ID: 16782459
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines.
Shen J; Huang C; Jiang L; Gao F; Wang Z; Zhang Y; Bai J; Zhou H; Chen Q
Biochem Pharmacol; 2007 Jun; 73(12):1901-9. PubMed ID: 17445779
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells.
Attoub S; Hassan AH; Vanhoecke B; Iratni R; Takahashi T; Gaben AM; Bracke M; Awad S; John A; Kamalboor HA; Al Sultan MA; Arafat K; Gespach C; Petroianu G
Eur J Pharmacol; 2011 Jan; 651(1-3):18-25. PubMed ID: 21074525
[TBL] [Abstract][Full Text] [Related]
20. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
